Document is current
Any future updates will be listed below
-
Authors
Ratajczak-Tretel, B.
Lambert, A. Tancin
Al-Ani, R.
Arntzen, K.
Bakkejord, G. K.
Bekkeseth, H. M. O.
Bjerkeli, V.
Eldøen, G.
Gulsvik, A. K.
Halvorsen, B.
Høie, G. A.
Ihle-Hansen, H.
Ihle-Hansen, H.
Ingebrigtsen, S.
Kremer, C.
Krogseth, S. B.
Kruuse, C.
Kurz, M.
Nakstad, I.
Novotny, V.
Næss, H.
Qazi, R.
Rezaj, M. K.
Rørholt, D. M.
Steffensen, L. H.
Sømark, J.
Tobro, H.
Truelsen, T. C.
Wassvik, L.
Ægidius, K. L.
Atar, D.
Aamodt, Anne Hege https://orcid.org/0000-0002-2824-2760
,
- License Information
-
More Information
Article History
Received: 4 March 2023
Accepted: 19 March 2023
First Online: 10 May 2023
Declarations
:
: AHA has received travel support, and honoraria for advice or lecturing from Bayer, Boehringer Ingelheim, BMS, Abbvie, Teva, Novartis, Roche, Pfizer, and Teva, research grant from Boehringer Ingelheim. DA has received honoraria and consultation fees from Actelion, Amgen, AstraZeneca, BMS/Pfizer, Bayer, Boehringer-Ingelheim, MSD, Novartis, Pharmacosmos, Roche Diagnostics, Sanofi, Takeda, and Vifor Pharma, and research funding (to the institution) from BMS/Pfizer, Bayer, Roche Diagnostics and Medtronic. BRT and ATL have received travel funding from Medtronic.
: The study was performed according to Helsinki Declaration and was approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REK 2013/2371) and local ethics committees in Denmark and Sweden. Written consent was obtained from all participants. Patients´ data were collected through the European Cerebrovascular Research Infrastructure (ECRI) and stored in the Services for Sensitive Data (TSD) at the University of Oslo. Study is registered at ClinicalTrials.gov (NCT02937077).
